Abstract
In parts of Asia, about 10% of the population have chronic hepatitis B virus (HBV) infection, and cancer patients who are HBV carriers are frequently complicated by HBV reactivation while receiving cytotoxic chemotherapy. The condition may result in varying degrees of liver damage, causing disruption in chemotherapy and compromising the patients’ prognosis. With the increasing use of chemotherapy paralleling the rise in breast cancer incidence, the occurrence of HBV reactivation is likely to further increase. Recent reports have suggested that the anti-viral agent, lamivudine, may reduce HBV reactivation and its associated morbidity. However, most studies are based on small series of lymphoma patients, while information on the other high risk population, namely breast cancer patients, has been lacking. In this study, we studied the role of lamivudine in preventing HBV reactivation and its associated morbidity in breast cancer patients with chronic HBV infection who were planned for chemotherapy. Two groups were studied. One group consisted of 31 patients who received ‘prophylactic lamivudine’ prior to and until 8 weeks after discontinuing chemotherapy. The other comprised of 61 historical controls who underwent chemotherapy without prophylactic lamivudine. The outcomes, in terms of the efficacy of lamivudine in reducing the incidence of HBV reactivation, and diminishing morbidity during chemotherapy were compared. The results revealed that in the prophylactic lamivudine group, despite a significantly higher proportion receiving anthracyclines, there was significantly fewer incidences of hepatitis (12.9 vs. 59.0%, p < 0.001), less HBV reactivation (6.5. vs. 31.1%, p=0.008), and less disruption of chemotherapy (16.1% vs. 45.9%, p=0.006). We conclude that prophylactic lamivudine significantly reduces the incidence of HBV reactivation and the overall morbidity of breast cancer patients undergoing chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
W Lee (1997) ArticleTitleHepatitis B infection N Eng J Med 337 17345–1745
ASF Lok CL Lai PC Wu (1987) ArticleTitleHepatitis B virus infection in Chinese families in Hong Kong Am J Epidemiol 126 492–499
Yeo W Chan PKS Zhong S et al. (2000) ArticleTitleFrequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 299–307
Galbraith RM Eddleston AL Williams R et al. (1975) ArticleTitleFulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy Lancet 2 528–530
Lok ASF Liang RHS Chiu EKW et al. (1991) ArticleTitleReactivation of hepatitis B virus replication in patients receiving cytotoxic therapy Report of a prospective study. Gastroenterology 100 182–188
Nokamura Y Motokura T Fujita A et al. (1996) ArticleTitleSevere hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies Survey in Japan, 1987–1991. Cancer 78 2210–2215
Kumagai K Takagi T Nakamura S et al. (1997) ArticleTitleHepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan Ann Oncol 8 107–109
W Yeo PKS Chan P Hui WM Ho KC Lam WH Kwan S Zhong PJ Johnson (2003) ArticleTitleHepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy: a prospective study J Med Virol 70 553–561
Yeo W Zee B Zhong S Chan PKS Wong W-L Ho WM Lam KC Johnson PJ (2004) ArticleTitleComprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 1306–1311
MP Coleman J Esteve P Damiecki A Arslan H Renard (1993) Trends in cancer incidence and mortality International Agency for Research on Cancer Oxford University Press Oxford, UK
Hong Kong Hospital Authority: Cancer incidence and mortality in Hong Kong 1993–1994. Hong Kong Cancer Registry, 1998
Silvestri F, Ermacora A, Sperotto A et al.: Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108(2): 394–396, 2000
M Persico F De Marino GD Russo (2002) ArticleTitleEfficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99 IssueID2 724–725
O Shibolet Y IIan S Gillis et al. (2002) ArticleTitleLamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers Blood 100 391–396
G Rossi A Pelizzari M Motta (2001) ArticleTitlePrimary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115 IssueID1 58–62
Fisher B, Brown AM, Dimitrov N et al.: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and flluorouracil in positive node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant breast and Bowel Project B-15. J Clin Oncol 8(9): 1483–1496, 1900
G Bonadonna A Valagussa A Moliterni (1995) ArticleTitleAdjuvant cyclophosphamide, and fluorouracil in node-positive breast cancer The results of 20 years follow-up N Engl J Med 332 901–906
FT Borg S Smorenburg RA De Man (1998) ArticleTitleRecovery from life-threatening corticosteroid-unresponsive chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43 IssueID10 2267– 2270
FL Clark MW Drummond S Chambers (1998) ArticleTitleSuccessful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin’s lymphoma. Ann Oncol 9 IssueID4 385–387
W Yeo JL Steinberg JS Tarn (1999) ArticleTitleLamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy J Med Viral 59 263–269
A Ahmed EB Keeffe (1999) ArticleTitleLamivudine therapy in chemotherapy-induced reactivation of hepatitis B virus infection Am J Gastroenterol 94 249–263
F Cainelli MS Longhi E Concia (2001) ArticleTitleFailure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 96 IssueID5 1651–1652
W Yeo PKS Chan HLY Chan (2001) ArticleTitleHepatitis B virus reactivation during cytotoxic chemotherapy- enhanced viral replication precedes overt hepatitis J Med Virol 65 IssueID3 473–477
GKK Lau HH Yin DY Fong HC Cheng WY Au LS Lai M Cheung HY Zhang A Lie R Ngan R Laing (2003) ArticleTitleEarly is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 IssueID6 1742–1749
W Yeo PKS Chan WM Ho B Zee KC Lam KIK Lei ATC Chan TSK Mok JJ Lee TWT Leung S Zhong PJ Johnson (2004) ArticleTitleLamivudine for the Prevention of Hepatitis B virus Reactivation in HBsAg Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. J Clin Oncol 22 IssueID5 927–934
Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942, 1998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yeo, W., Ho, W.M., Hui, P. et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88, 209–215 (2004). https://doi.org/10.1007/s10549-004-0725-1
Issue Date:
DOI: https://doi.org/10.1007/s10549-004-0725-1